Advertisement
U.S. markets open in 5 hours 38 minutes

Zevra Therapeutics, Inc. (1GDA.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
7.90+0.25 (+3.27%)
As of 08:12AM CET. Market open.
Advertisement
Show:
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
16,563
-
10,161
28,650
13,288
Cost of Revenue
1,089
-
222
2,059
1,305
Gross Profit
15,474
-
9,939
26,591
11,983
Operating Expense
59,660
-
34,841
18,862
16,764
Operating Income
-44,186
-
-24,902
7,729
-4,781
Net Non Operating Interest Income Expense
3,694
-
1,178
-115
-7,001
Other Income Expense
541
-
-3,081
-16,135
-1,012
Pretax Income
-39,951
-
-26,805
-8,521
-12,794
Tax Provision
-34
-
-33
34
-34
Net Income Common Stockholders
-39,917
-
-26,772
-62,897
-12,760
Diluted NI Available to Com Stockholders
-39,917
-
-26,772
-62,897
-12,760
Basic EPS
-1.16
-1.30
-1.20
-2.11
-3.21
Diluted EPS
-1.16
-1.30
-1.20
-2.11
-3.21
Basic Average Shares
34,400
35,452
34,489
29,766
3,981
Diluted Average Shares
36,212
35,452
34,489
29,766
3,981
Total Operating Income as Reported
-44,186
-
-42,565
7,729
-5,609
Total Expenses
60,749
-
35,063
20,921
18,069
Net Income from Continuing & Discontinued Operation
-39,917
-
-26,772
-8,555
-12,760
Normalized Income
-40,458
-
-23,695
3,224
-11,751
Interest Income
4,609
-
1,513
261
89
Interest Expense
915
-
335
376
7,090
Net Interest Income
3,694
-
1,178
-115
-7,001
EBIT
-39,036
-
-26,470
-8,145
-5,704
EBITDA
-38,517
-
-25,526
-7,888
-5,431
Reconciled Cost of Revenue
1,089
-
222
2,059
1,305
Reconciled Depreciation
519
-
944
257
273
Net Income from Continuing Operation Net Minority Interest
-39,917
-
-26,772
-8,555
-12,760
Total Unusual Items Excluding Goodwill
541
-
-3,081
-16,135
-1,012
Total Unusual Items
541
-
-3,081
-16,135
-1,012
Normalized EBITDA
-39,058
-
-22,445
8,247
-4,419
Tax Rate for Calcs
0
-
0
0
0
Tax Effect of Unusual Items
0.4604
-
-3.6972
-4,356
-2.6312